Recordati Industria Chimica e Farmaceutica S.p.A. (REC.VI)
Chart Events
Performance Outlook
| Previous Close | 38.76 |
| Open | 38.84 |
| Bid | 38.53 x 0 |
| Ask | 39.03 x 0 |
| Day's Range | 38.78 - 38.84 |
| 52 Week Range | 35.21 - 49.66 |
| Volume | |
| Avg. Volume | 4 |
| Market Cap | 8.161B |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | 22.84 |
| EPS (TTM) | 1.70 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.12 (2.74%) |
| Ex-Dividend Date | Nov 21, 2022 |
| 1y Target Est | N/A |
- Business Wire
Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology
PUTEAUX, France, August 31, 2022--Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The European Journal of Endocrinology.1 These data support the long-term utility of Isturisa® in the maintenance treatment of patients with Cushing’s disease and reinforce Isturisa as an effective and well-tolerated oral therapy. Isturisa® is indicated in the EU for the treatment of adult patients with en
- Business Wire
Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease
PUTEAUX, France, March 29, 2022--Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in The Journal of Clinical Endocrinology & Metabolism.1 These data reinforce Isturisa as an effective and well-tolerated oral therapy for patients with Cushing’s disease. Isturisa is indicated in the EU for the treatment of adult patients with endogenous Cushing’s syndrome,2 a rare and debilitating condition of hypercortisolism that is most commo
